Ira Schacter is a senior corporate partner in the Capital Markets Group and has been at the firm for 30 years. Ira represents clients in all aspects of corporate and financial matters, with extensive experience in mergers and acquisitions and complex structured finance. His practice consists principally of representing public and private acquirors, targets and private equity sponsors in connection with negotiated and contested mergers and acquisitions, restructurings, joint ventures and IP monetizations as well as other structured and complex financings.
In addition, Ira has worked extensively on transactions in the life sciences and technology sectors involving strategic alliances and commercialization collaborations, and intellectual property monetizations. Most notably, he has advised clients on the structure of royalty and patent stream monetizations, the purchase and sale of intellectual property assets, and the acquisition and disposition of IP-focused businesses and the securitization of virtually every type of cash flow producing asset.
Over the course of his career, Ira has been involved in virtually all aspects of the structured finance business with almost every type of securitization, including insurance risk, whole-company, and CLOs and with assets from the traditional to the varied, including corporate loans, swap receivables, repo, and other financial assets, as well as a variety of other unique assets, such as franchise royalties and shipping containers.
He received his B.A. in Economics from the State University of New York at Stony Brook; a J.D. from the Nova Center for the Study of Law, where he was a Notes and Comments Editor of the Law Review; and an LL.M. in corporations law from the New York University School of Law.
Representative recent transactions in which Ira had a leading role include:
•Salix Pharmaceuticals, Ltd. in its $15.6 billion acquisition by Valeant Pharmaceuticals International, Inc.
•Representing Mercuria Energy Group on its acquisition of J.P. Morgan's physical energy and commodities business.
•Representing Salix Pharmaceuticals on its terminated $2.5 billion inversion combination with Cosmo Technologies, a subsidiary of Cosmo Pharmaceuticals.
•Representing Acorda Therapeutics, Inc. in its $525 million acquisition of Civitas Therapeutics, Inc.
•Representing Exelon Corporation on its acquisitions of Integrys Energy Services, a retail electricity and natural gas company, and ETC ProLiance Energy, a natural gas marketing company.
•Representing Citigroup in a term loan financing for a special purpose entity to co-invest in a slate of films produced by Sony Pictures Entertainment.
•Representing Credit Suisse Securities (USA) LLC as sole structuring advisor and sole placement agent for a $50 million royalty bond financing by an indirect special purpose subsidiary of Danish pharmaceutical company Zealand Pharma, A/S, backed by stand-alone patent royalties and milestone payments from the licensee of Zealand's diabetes drug lixisenatide.
• Cadwalader Practices, Attorneys Featured in 2016 Chambers Global Guide
Mar 23, 2016
• Cadwalader Continues to Dominate Law-Firm Ranking
Jul 25, 2014
• Cadwalader Holds Position Atop Commercial MBS Representation Rankings
Aug 21, 2015
Clients & Friends Memos
• Final Credit Risk Retention Requirements for Asset-Backed Securities Transactions
Oct 30, 2014
• IMN's ABS East
Sep 21, 2014
• Quorum: February 2015 V3N1
Feb 11, 2015